Browse the evidence

Tirzepatid is being studied for its safety and efficacy as a treatment for obesity.

Practitioners should consider Tirzepatid as a potential treatment option for patients with obesity.

The iDiet does not recommend increasing exercise at the beginning of the program.

Practitioners should note that the iDiet's initial focus is on dietary changes rather than exercise.

Most participants in the PURE study consumed fewer than the recommended five daily portions of fruits and vegetables.

Efforts should be made to encourage higher fruit and vegetable consumption among populations.

Total repetition count for squat performance was lower at day 10 compared to day 8 within the 1.8g.kg-1.d-1 protein group.

Practitioners should monitor performance over consecutive training days, especially with lower protein intake.

Adherence to vegan and WFPB diets for ≥2 years is associated with lower BMI compared to <2 years.

Long-term adherence to vegan and WFPB diets may enhance weight loss outcomes.

One of two synergist muscles consistently demonstrated higher activity levels during the exercises.

Understanding which muscles are more active can help in designing targeted training programs.

Some patients may require weight loss beyond what lifestyle and behavioral modification can achieve.

Recognize that some patients may need additional interventions beyond lifestyle changes.

Obesity has a compelling influence on fertility and reproductive health.

Healthcare practitioners should consider the impact of obesity on reproductive health when treating patients.

Obesity in females is correlated with menstrual abnormalities, infertility, and complications during gestation.

Clinicians should assess reproductive health in obese female patients.

Tirzepatide has been approved by the FDA for type 2 diabetes in adults as a single dose weekly.

Practitioners can prescribe Tirzepatide for managing type 2 diabetes in adults.

Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity.

Practitioners should be aware of Tirzepatide's potential for treating obesity in clinical settings.

A ≥15% BMI reduction was associated with a 33% reduction in group health insurance payments at year 1.

Employers may see significant healthcare cost savings by supporting weight loss programs for employees.

Employees who lost ≤5% BMI had a 10% reduction in health expenditures.

Even modest weight loss can lead to some healthcare cost reductions.

Parameters of glucose metabolism improved as a result of the course.

Improving glucose metabolism can be a beneficial outcome of weight loss programs.

The course focused on psychological dangers associated with avoiding carbohydrates.

Incorporating psychological support in dietary programs can enhance effectiveness.

Parameters of glucose metabolism improved along with psychological indicators of eating impulses.

Improving glucose metabolism and psychological factors can enhance weight loss strategies.

Early genetic diagnostics can identify the type of obesity and guide therapy options.

Implementing genetic testing can enhance personalized treatment strategies for obesity.

Obesity is a chronic disease with significant physical and psychological impairments.

Practitioners should recognize obesity as a serious chronic condition requiring comprehensive management.

There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery.

Practitioners should consider integrating pharmacotherapy with lifestyle changes and surgical options for comprehensive obesity management.

There is an urgent need for a structured, customized and evidence-based clinical practice guideline for the management of obesity in Bangladesh.

Practitioners should advocate for and implement structured guidelines for obesity management.

GLP-1 agonists improve blood glucose profiles and reduce cardiovascular risk.

GLP-1 agonists can be recommended for improving glycemic control and reducing cardiovascular risks in diabetic patients.

Dual GIP/GLP-1 agonists are more effective in treating obesity than GLP-1 agonists alone.

Consider dual GIP/GLP-1 agonists for potentially better outcomes in obesity treatment.

Patients treated with semaglutide experienced a greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo, with an estimated treatment difference of 7.8 points (P < .001).

Semaglutide may be an effective treatment option for improving heart failure symptoms in obese patients.

Serious adverse events were lower in the semaglutide group (13.3%) compared to the placebo group (26.7%) (P < .001).

Semaglutide may offer a safer treatment option for this patient population.